This newslink doesn't exist or it was removed.
Go to Homempage.
RTTNews USA Health October 10, 2023
Biotechnology company Inovio Pharmaceuticals, Inc. () announced Tuesday that it has received feedback from the U.S. Food and Drug Administration (FDA) that data from its completed Phase 1/2 trial of INO-3107 for the treatment of RRP could support INOVIO's submission of a... + más
INOVIO Says FDA Grants Breakthrough Therapy Designation For INO-3107; Stock Up 15% | RTTNews
INOVIO Reports Positive Interim Phase 1/2 Trial Results For INO-3107 For Respiratory Papillomatosis | RTTNews
RTTNews USA Health September 07, 2023
Biotechnology company Inovio Pharmaceuticals, Inc. () announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis (RRP).The... + más
Inovio Pharma Receives FDA Feedback On Submission Of BLA For INO-3107 To Treat RRP | RTTNews
RTTNews USA Health October 13, 2022
Biotechnology company Inovio Pharmaceuticals Inc. () announced Thursday positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.In the first cohort... + más
Surge of respiratory illnesses in children straining some hospitals' capacity | ABC News
NKorea launches 2 missiles toward sea after US-SKorea drills | ABC News
RTTNews USA Health February 02, 2023
Biotechnology company INOVIO Pharmaceuticals, Inc. () announced Thursday positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo.In the trial,... + más
Eye drops recalled after 55 reports of bacterial infection, 1 death in 12 states | ABC News
RTTNews USA Health January 03, 2024
INOVIO () announced plans to submit a BLA for INO-3107 as a potential treatment for Recurrent Respiratory Papillomatosis in the second half of 2024. This followed an Initial Comprehensive Multidisciplinary Breakthrough Therapy Meeting with the FDA on critical aspects of the data... + más
About iurex | Privacy Policy | Disclaimer |